$1,150,000 of CENCORA INC. lobbying was just disclosed, from Q1 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Ensuring Community Access to Pharmacist Services Act (H.R. 3164)/Equitable Community Access to Pharmacist Services Act (S.2426) Inflation Reduction Act implementation, including impact on Pharmacy & Physician Reimbursement Extend payment increase under CMS FY 2026 Medicare's Part B physician fee schedule. Protecting Patient Access to Cancer and Complex Therapies Act 2025 (H.R.4299) Reimbursement policies impacting drug shortages Part B drug pricing changes Preventing and Mitigating Generic Drug Shortages CMS FY 2026 Medicares Part B Physician Fee Schedule: Proposed Changes to Bonafide Service Fees Preventing and Mitigating Generic Drug Shortages Ensuring Seniors Access to Critical Medications Act (H.R. 3164)/Equitable Community Access to Pharmacist Services Act (S.2426)- Impacts to pharmacy Part D drug pricing in Inflation Reduction Act (IRA) Support for Fair Pharmacy Reimbursement Essential Medicines Strategic Stockpile Department of Defense Essential Medicines Strategic Stockpile Prescription Information Modernization Act (H.R.4132/S.2027) Mitigation of Drug Shortages Pharmaceutical supply chain resilience National Defense Authorization Act FY2026 (NDAA) Supply Chain Resiliency Most Favored Nation drug pricing proposals Direct to Consumer proposals CMS Medicare Part B Physician Fee Schedule Rule Break Up Big Medicine Act (S. 3822) CMS FY 2026 Medicares Part B Physician Fee Schedule: Proposed Changes to Bonafide Service Fees Role and value of community specialty physicians and MSOs Global Intangible Low-taxed Income (GILTI) Territorial Economic Recovery Act (H.R. 363) The Medical Manufacturing, Economic Development, and Sustainability (MMEDS) Act (H.R. 3042) Restore Economic Vitality and Investment in the Virgin Islands Act (REVIVE VI Act) (858) Tariff proposed policies"
You can find more data on corporate lobbying on Quiver Quantitative.
COR Insider Trading Activity
COR insiders have traded $COR stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $COR stock by insiders over the last 6 months:
- ROBERT P. MAUCH (President & CEO) has made 0 purchases and 4 sales selling 19,050 shares for an estimated $6,776,655.
- LAZARUS KRIKORIAN (SVP & Chief Accounting Officer) sold 4,031 shares for an estimated $1,383,580
- ELIZABETH S CAMPBELL (Executive Vice President) sold 3,351 shares for an estimated $1,146,377
- SILVANA BATTAGLIA (Executive Vice President) sold 1,677 shares for an estimated $578,565
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
COR Hedge Fund Activity
We have seen 638 institutional investors add shares of COR stock to their portfolio, and 636 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 4,321,566 shares (-73.2%) from their portfolio in Q4 2025, for an estimated $1,459,608,916
- FMR LLC added 2,148,227 shares (+64.9%) to their portfolio in Q4 2025, for an estimated $725,563,669
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 2,085,473 shares (+80.9%) to their portfolio in Q4 2025, for an estimated $704,368,505
- MARSHALL WACE, LLP removed 1,839,818 shares (-92.2%) from their portfolio in Q4 2025, for an estimated $621,398,529
- VIKING GLOBAL INVESTORS LP removed 1,778,135 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $600,565,096
- CITADEL ADVISORS LLC removed 1,185,912 shares (-95.8%) from their portfolio in Q4 2025, for an estimated $400,541,778
- PRICE T ROWE ASSOCIATES INC /MD/ removed 731,075 shares (-9.5%) from their portfolio in Q4 2025, for an estimated $246,920,581
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
COR Analyst Ratings
Wall Street analysts have issued reports on $COR in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Morgan Stanley issued a "Overweight" rating on 01/29/2026
- TD Cowen issued a "Buy" rating on 11/10/2025
- UBS issued a "Buy" rating on 11/07/2025
- Mizuho issued a "Outperform" rating on 11/06/2025
- Baird issued a "Outperform" rating on 11/06/2025
To track analyst ratings and price targets for COR, check out Quiver Quantitative's $COR forecast page.
COR Price Targets
Multiple analysts have issued price targets for $COR recently. We have seen 11 analysts offer price targets for $COR in the last 6 months, with a median target of $400.0.
Here are some recent targets:
- John Belton from Evercore ISI Group set a target price of $360.0 on 04/08/2026
- Glen Santangelo from Barclays set a target price of $425.0 on 02/13/2026
- Stephen Baxter from Wells Fargo set a target price of $429.0 on 02/10/2026
- Lisa Gill from JP Morgan set a target price of $419.0 on 02/10/2026
- Erin Wright from Morgan Stanley set a target price of $400.0 on 01/29/2026
- Brian Tanquilut from Jefferies set a target price of $440.0 on 01/22/2026
- Michael Funk from B of A Securities set a target price of $360.0 on 01/05/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
